There was no magical numbing cream, of course (at least, not that I knew of at the time). But the doctor got it: He took a ...

As of 1:14:09 PM EST. Market Open. Scilex (SCLX) announced that Pain Medicine News published retrospective claims data on ZTlido vs. lidocaine 5% patch. Pain Medicine News, the premier trade ...

lidocaine 5% patch. Pain Medicine News, the premier trade publication in the pain management space, published decreased opioid utilization demonstrated with ZTlido in the magazine’s December ...

Patch testing ... study of 20 patients successfully treated with a 5% lidocaine medicated plaster for localized neuropathic pain was undertaken to assess the efficacy and tolerability of the ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of ...

Joan Vassos thought her life was over after the passing of her first husband, John. Knowing that their time together had come ...

In a turbulent market environment, SCLX stock has reached a 52-week low, trading at $0.33, with a market capitalization of $62.12 million. This price level reflects a significant downturn for the ...

The pharmacokinetics, safety, and tolerability of four topical lidocaine patches 5% continuously applied for 72 hours and changed every 12 or 24 hours were examined. In this randomized ...

The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...

Pain MD, which once ran as many as 20 clinics across three states, gave chronic-pain patients about 700,000 total injections ...

When patients can’t access their MHT patches, they may consider switching to different formulations, such as tablets or gels.